Population-based, risk-stratified genetic testing for ovarian cancer risk: a focus group study by Meisel, SF et al.
E-Mail karger@karger.com
 Original Paper 
 Public Health Genomics 2013;16:184–191 
 DOI: 10.1159/000352028 
 Population-Based, Risk-Stratified
Genetic Testing for Ovarian Cancer Risk: 
A Focus Group Study 
 S.F. Meisel a    L. Side b    L. Fraser b    S. Gessler b    J. Wardle a    A. Lanceley b 
 a  Health Behaviour Research Centre, Department of Epidemiology and Public Health, and  b  Department of
Women’s Cancer, UCL Institute for Women’s Health and NIHR University College London Hospitals Biomedical 
Research Centre,  London , UK 
pated to result in a false sense of immunity. Unexpectedly, 
participants also wanted to receive cancer prevention ad-
vice in conjunction with genetic testing; screening alone was 
not regarded as sufficient.  Conclusion: The encouraging re-
sults from this small study warrant further large-scale re-
search into risk-stratified OC screening. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Cancer survival depends strongly on stage at diagno-
sis, with earlier stage diagnoses resulting in more favour-
able outcomes  [1] . Although progress has been made in 
improving early diagnosis for many cancers, timely de-
tection of ovarian cancer (OC) remains a challenge  [2] . 
The absence of a distinct ‘pre-cancerous’ stage, in combi-
nation with the relatively low population frequency of the 
disease, has meant that ‘traditional’ screening approaches 
are not feasible  [3] , leading to a quest for alternative strat-
egies to identify OC early in both the general and the 
higher risk population  [4–6] .
 Genetic testing for germline mutations associated with 
higher risk of OC is becoming increasingly affordable and 
offers an opportunity to identify higher risk women be-
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 Abstract 
 Study Purpose: A population-based risk stratification pro-
gramme for ovarian cancer (OC) may improve OC survival by 
identifying women at increased risk and implementing an 
appropriate risk management strategy. The present study 
explored attitudes towards an OC risk stratification pro-
gramme incorporating predictive genetic testing and risk-
stratified screening as part of a larger study investigating OC 
screening.  Methods: Focus groups consisting of 56 mem-
bers of the general public (mean age 45 years; 34% non-
white) were conducted using a hypothetical scenario. The 
group sessions were recorded, transcribed verbatim and an-
alysed using Framework Analysis.  Results: There was strong 
support for the proposed programme. Genetic testing and 
risk-stratified screening was thought to raise awareness, of-
fer reassurance and offer opportunities for early interven-
tion. Anxiety was only mentioned in relation to receiving a 
diagnosis of OC and not with screening per se. Perhaps be-
cause lay models of cancer already embrace both environ-
mental and genetic factors, a low-risk result was not antici-
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fore OC develops, irrespective of known family history. 
This raises the possibility of more intense screening in 
those at higher risk, potentially improving treatment out-
comes and survival  [6] . Mutations in the  BRCA1 and 
 BRCA2 genes increase the lifetime risk of OC by age 70 
by 39–65, and 11–37%, respectively, but these mutations 
are rare  [7–9] . Mutations in other genes are more com-
mon, influencing OC development despite low pene-
trance  [10] . Combined testing for several genes so far as-
sociated with increased OC risk, in conjunction with 
more ‘traditional’ risk factors (age, family history, parity, 
and oral contraceptive pill use), may lead to more accu-
rate risk estimation than any approach in isolation  [5] .
 Attitudes towards genetic testing for  BRCA1/2 muta-
tions have been explored extensively, particularly in indi-
viduals with a family history of breast cancer. A review of 
the literature in 2006 found high levels of interest in ge-
netic testing among women with a family history (80–
90%), although actual test uptake tends to be lower 
( ∼ 60%). In general population samples, interest in testing 
is lower (50–70%), although test uptake is comparable 
 [11] . Other factors that have been associated with uptake 
are older age [e.g.  12] , Ashkenazi Jewish heritage [e.g.  13] 
and being unmarried  [14] , although studies have been 
heterogeneous in approach, sample size and statistical 
analyses. This makes it difficult to draw definite conclu-
sions about who would be most likely to undergo testing.
 One barrier to implementation of population-based 
genetic testing for OC risk is the concern about adverse 
psychological reactions  [15, 16] . Evidence from studies 
using  BRCA1/2 testing shows that in the majority of stud-
ies, genetic test feedback was perceived as positive in car-
riers and non-carriers alike, and negative psychological 
outcomes tended to be short-lived  [17–20] . However, 
these findings stem largely from studies of highly selected 
groups who were well aware of the possibility of increased 
risk prior to testing, so the results need to be viewed with 
caution.
 One study has assessed the effects of receiving genetic 
test feedback for a range of conditions, including breast 
cancer risk, in a large general population sample  [21] . In-
terested individuals who accessed the Navigenics website 
without prompting could obtain the ‘Navigenics Health 
Compass’ (http://www.navigenics.com) at a reduced rate 
in return for responding to a survey 6 months after view-
ing their genetic test results. Intentions to screen for vari-
ous cancers increased significantly in the whole sample, 
with no increase in negative affect at the 6-month follow-
up. However, in this study, genetic feedback was given for 
over 23 conditions, which would likely generate raised risk 
for some conditions and lowered risk for others, poten-
tially leading to a null effect in overall risk perception and 
hence no increase in negative affect. Reactions to genetic 
test feedback for a single, serious condition, in a popula-
tion largely unaware of their genetic risk, may be different.
 The present study explored attitudes towards an OC 
risk stratification programme incorporating predictive 
genetic testing and risk-stratified screening for OC. As 
this is a relatively new area, a qualitative methodology was 
used, with focus groups from the general public who are 
asked to consider how they might respond to the oppor-
tunity of genetic testing and risk-stratified screening. Hy-
pothetical scenarios are an important step when imple-
menting novel technologies, both to ascertain any likely 
adverse reactions and to gain insight into facilitators and 
barriers to their use  [22] .
 Materials and Methods 
 Participants 
 Participants were 56 members of the general public, recruited 
by Saros UK, a qualitative recruitment service with a participant 
database of over 250,000. Individuals from a range of ages, socio-
economic backgrounds and ethnicities from London and sur-
rounding areas were invited. We specified ‘not currently affected 
by cancer’ as the only exclusion criterion because we were inter-
ested in views from a broad segment of the general public. Partici-
pants were selected on a first-come-first-serve basis based on avail-
ability. They were seen in 7 focus groups of 6–9 individuals each 
(mean n = 7). One group of 9 men was included because men can 
pass genetic mutations on to female offspring. Participants were 
reimbursed with 30 GBP for their time and effort. Participant char-
acteristics are displayed in  table 1 .
 Procedure 
 Ethical approval was obtained from the University College 
London Ethics Committee for non-NHS Research (project ID 
3162/001). After participants had signed consent forms and pro-
Table 1.  Demographic characteristics of the samp le (n = 56)
% (n)
Mean age ± SD, years 44.9 ± 13.2
Ethnicity (white) 66.0 (37)
Education (higher degree) 55.3 (31)
Employment (full-time) 39.2 (22)
Marital status (married) 33.9 (19)
Living arrangement (homeowner) 51.7 (29)
Lifetime screening (mammogram/
Pap/FoBt/prostate men) 73.2 (41)
Cancer within social network 78.5 (44)
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vided brief demographic information, the focus group moderator 
(S.M.) introduced herself, the funding source (Cancer Research 
UK) and the topic of discussion. Participants were informed that 
the discussion would be recorded, but all answers were confiden-
tial and anonymity would be maintained. It was made clear that 
there were no right or wrong answers and that we were interested 
in each person’s views. A focus group guide using some predefined 
questions was used to ensure all important topic areas were cov-
ered ( table 2 ). Efforts were made to keep questions open by using 
a non-directive questioning style and to include participants who 
appeared to be less forthcoming by asking them directly about 
their thoughts. The focus group moderator moved on to the next 
topic only when it was felt that the discussion came to a natural 
conclusion or no new answers were forthcoming.
 Table 2 displays the questions asked in each section. Questions 
were chosen after examining the literature pertaining genetic test 
feedback and cancer and discussions within the research team on 
the basis that they would best cover the area of interest. First, par-
ticipants were asked about their awareness of OC. Then they were 
given a brief presentation (5 slides) about the contribution of genes 
to OC, the existence of a genetic test, and the idea of population-
based, risk-stratified screening. The presentation was based on ex-
isting OC information leaflets widely available in the UK (e.g. 
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/
Ovary/Aboutovariancancer/Aboutovariancancer.aspx), explain-
ing all concepts in lay terms. We opted for a presentation over writ-
ten information to ensure the information participants received 
was unaffected by their literacy. Participants were told that in the 
proposed stratified screening programme a number of risk factors 
would be combined to give an individual risk estimate and that 
genetic testing would be part of this assessment. It was explained 
that  BRCA1/2 mutations were rare but would confer high risk, 
whereas mutations in other genes were more common but would 
raise OC risk only marginally. This was reinforced by telling par-
ticipants explicitly that they would be unlikely to have a rare 
 BRCA1 or  BRCA2 mutation, but more likely to have one or more 
of the more ‘common’ genetic mutations, which would raise OC 
risk to an intermediate level. They were asked about (i) their un-
derstanding of the issues covered in the slides, (ii) their opinions 
about undergoing genetic testing and risk-stratified screening, and 
(iii) their thoughts and opinions about risk management, includ-
ing up to 4-monthly screening for those identified at ‘higher risk’. 
Participants were not explicitly informed about risks of screening 
or what primary preventive options entailed because we wanted to 
explore whether they would request this kind of information, but 
they were discussed when the question arose. Before concluding 
the group, participants had the opportunity to express any issues 
not mentioned earlier and were directed to relevant sources of in-
formation about OC (Macmillan and Cancer Research UK web-
sites).
 Analysis 
 Focus group recordings were transcribed verbatim and coded 
using framework analysis  [23] . This method is appropriate because 
it allows data analysis by group and theme. It also provides a sim-
ple way of differentiating between common and rare themes. 
Transcripts were read and reread. A matrix (framework) contain-
Table 2.  Focus group guide (themes, information and questions)
General attitudes towards ovarian cancer risk and their 
experience of it
Knowledge, how common is it?, symptoms
Do you feel at risk?, what are the risk factors?
Anything that you can do to reduce the risk of ovarian 
cancer?
Opinions on understanding genetic information 
(Participants presented with slides on genetic risk)
Does the genetic risk information make sense?
Would you be interested in receiving genetic information?
How would you like to receive it? 
(in what format?/from who?, etc.)
Opinions on a screening programme using risk stratification 
approach
Mod: Risk stratification means that women can be grouped based 
on their likelihood of getting ovarian cancer. Women can be 
described as having a low, intermediate or high risk. The level of 
risk is based on a woman’s genetic risk and other risk factors. 
Identifying genetic risk involves having a blood test. Identifying 
other risk factors would involve filling in questionnaires about 
family history, background and health information. Scientists 
can then put all of this information together and estimate 
whether a women is at low, intermediate or high risk.
It is estimated that 50 – 60% of women will be at low risk,
30 – 45% at intermediate risk, and 4 – 7% at high risk.
What do you think about a risk stratified approach to 
screening? (pros, cons)
Would you like to have a screening test for ovarian cancer 
risk?
How would you feel if you were told that you were at
low/intermediate/high risk?
Do you see risk stratification as a positive, neutral or negative 
development in screening provision?
Opinions on possible risk management options
Mod: Depending on a woman’s risk level (low, intermediate or 
high), she would receive different levels of risk management
for ovarian cancer. Women at low risk would receive 
information telling them that they are at low risk and that they 
do not need further monitoring. This information would also let
low-risk individuals know about symptoms of ovarian cancer. 
Women at intermediate risk would receive screening every year 
(screening involves a blood test to check for levels of the 
biomarker CA-125 followed by transvaginal ultrasound). Those 
at high risk would be screened every 4 months. High-risk women 
may also be referred to a specialist to discuss risk-reducing 
surgery.
What to do you think of the risk management options?
(e.g. reassurance, annual, 4 monthly)
How would you feel if you were in the low/intermediate/high 
risk management group?
What are the pros and cons of this approach?
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ing common emerging themes was developed by categorising 
statements loosely at first, then developing more detailed themes 
as statements within a category increased. As new themes emerged, 
they were added to the matrix. Analysis was both inductive and 
deductive because the semi-structured format of the focus groups 
ensured that predetermined areas were covered while allowing 
emergence of new concepts from the participants. All transcripts 
were independently coded by S.M. and a researcher not involved 
in the study to assess validity and inter-rater reliability. After cod-
ing, the raters discussed any differences. Agreement was high, but 
where minor discrepancies arose, transcripts were reread and dis-
cussed until agreement was reached. For example, in some quotes, 
it was unclear whether women spoke from their own experience or 
whether they spoke about other women’s possible responses. Here, 
both raters discussed the context in which the statement was made 
to decide on its most likely meaning.
 Results 
 Awareness of OC and Its Risk Factors 
 OC awareness was consistently low. Some women indi-
cated that the general lack of awareness demonstrated that 
OC is ‘not one of the cancers to worry about’. Many had 
never thought about OC, and consequently did not feel at 
risk of developing it. A few women who had thought about 
OC cited a news story about a UK celebrity who died of 
cervical cancer as primary reason. Several women believed 
that cervical screening would test for all ‘women’s cancers’, 
and they were surprised to hear that this was not the case.
 Women either had no knowledge about risk factors, or 
named risk and protective factors very tentatively after 
direct probing. This appeared to be partly due to a wide-
spread assumption that risk reduction would be cancer-
specific: ‘If you smoke you are increasing your chances of 
lung cancer. You know if you smoke and drink heavily, 
you are increasing your risk of throat cancer […]’, and 
therefore, there was a perception that many common risk 
factors would not be relevant for developing OC. Confu-
sion with cervical cancer was also frequent and hysterec-
tomy was often mentioned as reducing or abolishing risk.
 Awareness of Genes Affecting Cancer 
 All participants were aware that cancer ‘runs in fami-
lies’, and that genes play a role. Non-white participants 
frequently mentioned family ties and inheritance pat-
terns and gave relatively accurate descriptions about the 
role of genes in cancer development, for example: ‘Gener-
ally, the genes that are prevalent to cancerous symptoms 
lie dormant until there is some trigger, like stress, and 
then the gene can kind of switch on, if you like, and you 
end up with cancer’. When asked directly, men acknowl-
edged that they could pass on genes for OC to their off-
spring, but it was apparent in the discussion that it was 
not on their minds. Women often spontaneously cited a 
responsibility to be tested in order ‘not to pass anything 
bad on to [their] children’.
 Reactions to the Idea of Genetic Testing for OC Risk 
 Genetic Testing is Generally Embraced 
Perhaps because participants were already aware of 
the genetic component to cancer, genetic testing for OC 
risk was seen as indisputably beneficial and no apprehen-
sions were expressed. Many women drew on their experi-
ence with existing cancer screening programmes to note 
the importance of surveillance. The common view was 
that knowledge about OC risk would be empowering, es-
pecially because ‘being aware of this now, actually read-
ing up on it and getting as much information as possible, 
finding out what new technologies they are coming out 
with, and preventative measures […]’ would allow wom-
en to prepare for the future. Having genetic information 
on file was seen as aid to receiving better and more tar-
geted care because ‘doctors would then have something 
to go on, it wouldn’t be sort of... Oh, it’s just indigestion’. 
The option of not necessarily having to know the test re-
sult, but it being ‘on file’ for the healthcare provider, was 
introduced by those anticipating anxiety in response to 
their result as a hypothetical option of deriving the ben-
efits from screening without inducing negative affect. 
Concerns about ethics, privacy, insurance issues, or the 
potential of using DNA unlawfully were not mentioned 
at all in the discussion, neither was the idea of DNA being 
in any way ‘special’.
 Anticipated Reactions to Risk-Stratified Screening 
 Discussion in the Focus Groups Gravitated towards 
the Consequences of the Test Result, rather than the 
Idea of Risk-Stratified Screening per se 
Risk-stratified screening after risk assessment incor-
porating genetic testing was received with enthusiasm 
throughout. In fact, in some groups the idea was brought 
up before the moderator introduced it: ‘Why not just have 
an umbrella genetic screening to show prevalence and 
maybe initially to start with one particular age group that 
has propensity to acquire cancer of some description at a 
certain stage in life?’ All participants took follow-up 
screening after genetic testing for granted and even ex-
pected it, especially for those at higher risk. However, 
screening was seen as a way to eventually detect cancer.
It was not seen as protective or as a risk management 
strategy.
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 Worry was predominantly expressed in the context of 
coping with a diagnosis of OC, not with the screening: ‘If 
I did have it [the gene] I think I wouldn’t want to go for 
the treatment [screening], I’d just say, take my ovaries 
away, take them away’ .  Most women felt that their reac-
tion would depend on their knowledge of OC, including 
symptoms, life expectancy after diagnosis, potential for 
metastasis, and cancer treatment options because ‘if 
somebody says, yes, if it’s caught early it’s totally curable, 
right, ok, high risk, well, no big deal’.  The likely frequen-
cy of OC screening required for ‘higher risk’ women was 
seen as potentially anxiety-inducing, but providing infor-
mation on OC was viewed as helping to keep anxiety to a 
minimum. The predominant view by far was that screen-
ing would become increasingly ‘normal’ or ‘routine’ over 
time. Furthermore, the idea of being able to get advice and 
be ‘fast-tracked’ when classified at ‘higher risk’, if there 
were any worries about symptoms, mitigated potential 
anxieties for many participants.
 The Need for Prevention Advice as an Adjunct to the 
Test Result 
All participants expressed a strong desire to receive 
lifestyle advice about how to lower OC risk. Although 
there was some sense of the inevitability of cancer devel-
opment (sometimes healthy people can be ‘struck by can-
cer’), many participants appeared to believe that behav-
iour change ‘must’ be effective in OC prevention. Screen-
ing attendance was not seen as a preventive action, but 
merely a means of early detection: ‘Being told that you are 
high risk and all we are going to do is do a blood test every 
three months but there’s no advice we can give you about 
changing your lifestyle, I think that’s downright cruel’.   In 
particular, a higher risk result was anticipated to be a 
‘wake-up call’ to engage with behaviour change. The need 
to feel ‘in control’ over cancer development was a central 
theme in the discussion. Despite some understanding of 
genetic risk, there was an assumption that individuals 
could move between risk categories, with OC being per-
ceived as both a ‘given’ and something that could be pre-
vented, and participants regularly switching between the 
2 perspectives within the course of the discussion.
 No Evidence for Complacency with a Lower-Risk 
Result 
Because participants were aware that genes are not ful-
ly indicative of cancer risk, a lower risk result was not seen 
as reason to be complacent: ‘You would be relieved but 
you wouldn’t be complacent because even if it’s a low risk, 
you could still get it; it’s not inevitable that you wouldn’t’. 
 However, few women expressed concerns about further 
routine screening being unavailable following a lower risk 
result, although some wanted screening to be available on 
request. Without direct probing, there was little focus on 
reactions to an intermediate genetic risk result, but those 
who thought about it mentioned that it would increase 
their symptom awareness and prompt them to seek out 
information.
 Discussion 
 Although practical barriers to implementation would 
have to be overcome  [16] , the findings of this qualitative 
study suggest that women would welcome the opportu-
nity of genetic testing and subsequent risk-stratified 
screening for OC. They did not anticipate adverse psy-
chological effects in response to the personal genetic test 
result, although a ‘higher risk’ result was often described 
as a ‘wake-up call’ for taking preventive action. On the 
contrary, the idea of a genetic test result being available 
to their healthcare provider was received with enthusi-
asm, even by individuals who anticipated some emo-
tional discomfort because it was seen as a means of re-
ceiving more targeted, rapid and better care. Although 
these findings differ somewhat from earlier studies in-
volving  BRCA1/2 testing for risk of breast cancer, which 
have shown increased, albeit short-lasting, distress and 
anxiety after testing [e.g.  24, 25] , this may be because the 
current study used a hypothetical scenario. One limita-
tion of this methodology is that people may have diffi-
culty imagining themselves being negatively affected 
 [26] . Alternatively, results may differ because partici-
pants in previous  BRCA  studies were from families high-
ly affected by cancer where the gene penetrance is much 
higher and not from the general population; experience 
of cancer in the family, and not the genetic test result per 
se, may have been responsible for some of the negative 
emotional reactions. It is also possible that the general 
public’s growing familiarity with genetics and awareness 
of the genetic contribution to cancer  [27] are contribut-
ing to reduced concerns about ethics, privacy, or a ‘spe-
cial’ status of DNA and an inherited susceptibility to 
cancer.
 Despite the information that it would be unlikely to be 
found to have mutations in the  BRCA1/2 genes, and that 
‘common’ OC genetic mutations would raise risk only 
modestly , a ‘higher risk’ result was frequently discussed 
as if it denoted being highly likely to develop OC. It is pos-
sible that participants retained only the ‘gist’ of the risk 
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information, including a binary (high vs. low) under-
standing as described in the Fuzzy Trace model  [28] , lead-
ing to misperceptions about the likelihood of cancer de-
velopment. Alternatively, talking about ‘higher risk’ in 
the cancer context may have activated neural networks 
associated with cancer development and diagnosis, which 
in turn elicited networks associated with coping and 
treatment, as suggested by the Spreading Activation the-
ory  [29] . This could explain why the discussion about re-
actions to test feedback immediately focused on scenarios 
surrounding OC diagnosis and potential coping strate-
gies, and why most participants ignored the ‘lower risk’ 
and ‘intermediate risk’ scenarios in discussion unless 
probed directly. Either way, the findings suggest that a 
better understanding of the cognitive processes that in-
fluence risk perception is important, and they highlight 
the need to provide information on the likelihood of can-
cer development in a format that is easy to understand 
and remember, both before testing and alongside the ge-
netic test result.
 Fears that a ‘lower risk’ result would induce compla-
cency did not receive much support. This may be because 
lay models of cancer development already incorporate 
the idea of genetic and environmental causal factors op-
erating in parallel  [30] , so most people are aware that low-
er genetic risk does not mean immunity to OC. However, 
individuals trusted the genetic test to accurately identify 
risk, and there was no suggestion that those at lower risk 
would seek unnecessary screening. There was a notion 
that more frequent screening should be available to indi-
viduals who were worried after risk assessment regardless 
of risk category, but this was less pronounced than in a 
similar study about genetic testing and stratified screen-
ing for breast cancer  [31] . This could be because breast 
screening is an established programme and has, there-
fore, become an ‘acquired right’ or because OC awareness 
is lower than breast cancer awareness and OC is, there-
fore, seen as less of a threat. The accuracy of either theory 
could be explored in further research.
 Although participants viewed risk-stratified screening 
favourably, they were also adamant about the need for 
information on preventive action against OC develop-
ment. Screening was  expected after genetic testing and 
was even suggested before introduction by the moderator 
in some focus groups. However, while it was seen as
helpful for ‘catching OC early’, it was perceived to be la-
mentably inadequate for cancer control. Misperceptions 
about the purpose of screening in the general public may 
perhaps be at the heart of this finding. Among the medi-
cal profession, screening is regarded as a ‘secondary pre-
vention’ strategy, aimed at reductions in morbidity and 
mortality; whereas the general public may only see ‘pri-
mary prevention’ (avoiding disease development alto-
gether) as ‘effective’ prevention, while screening is ‘early 
detection’ which means they would still receive a cancer 
diagnosis. Further research may be warranted to investi-
gate this issue in more detail. Participants saw tangible 
advice on taking preventive action as integral to any risk 
assessment programme, and the suggestion of omitting it 
(because there is no solid evidence on prevention) was 
met with disbelief. These attitudes seem to reflect the as-
sumption that a key role of genetic test feedback is to mo-
tivate disease prevention, a perspective that appears to be 
widely held in the general public and is promoted by com-
panies marketing genetic testing directly to consumers 
(www.23andme.com; www.decodeme.com), despite lim-
ited supportive evidence  [32] . Regardless of the behav-
ioural impact of preventive advice, the results of the pres-
ent study suggest that the acceptability of any genetic test-
ing programme depends in part on cancer prevention 
advice being made available.
 The call for cancer prevention advice is also reflective 
of beliefs about individual control over cancer that are 
prevalent in Western society  [33] . However, at the same 
time as believing that there must be strategies for disease 
prevention, many participants also characterised cancer 
as unpredictable or inevitable, and the 2 perspectives of-
ten existed in parallel. ‘Switching’ between perspectives 
occurred without hesitation, suggesting that people are 
unaware of any inconsistency. It would be useful to inves-
tigate the cognitive processes underlying beliefs about 
cancer to try to understand how contradictory views are 
formed and maintained.
 The present study has limitations. It was based on a hy-
pothetical scenario and, therefore, is only indicative of pos-
sible reactions to an actual opportunity for genetic testing 
for OC. Although the focus group participants were enthu-
siastic about the prospect of a genetic test, actual uptake is 
difficult to predict because intentions and behaviour cor-
relate only weakly in this area  [34, 35] . The qualitative for-
mat of the study means that the sample was small, and the 
results cannot be assumed to be representative of the UK 
population. Despite inclusion of individuals from a variety 
of ages, social strata and ethnicities, they were members of 
a recruitment agency and had self-selected into the study, 
and may be different from the general population. A larger, 
quantitative study is needed to draw conclusions about the 
range and frequency of the views presented here for the 
wider population. Furthermore, as with any qualitative 
study, analysis and interpretation are always coloured by 
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the researchers’ culture and preconceived notions. We at-
tempted to minimise bias by working as a team on the 
study, meeting frequently and discussing methods and 
procedure in detail. Lastly, focus groups always carry the 
risk of more outspoken participants overshadowing those 
who are more introverted, distorting the picture of true 
opinions presented  [36] . To minimise this, we moderated 
the groups to reduce the chance of any one person domi-
nating the conversation, and specifically addressed indi-
viduals who were less outspoken, to ensure that everyone 
had the opportunity to express their views; however, some 
variation in participation levels remained. The focus group 
format is also a strength because it allows an in-depth anal-
ysis of responses to a novel healthcare technology and 
makes it cost-effective to include a larger number of par-
ticipants than in one-on-one interviews.
 Conclusion 
 These results provide a first indication that the public 
may be broadly positive about the offer of population-
based genetic testing for OC risk and would support risk-
stratified screening as long as cancer preventive advice 
was offered alongside the programme.
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